Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) has a beta value of 1.05 and has seen 0.59 million shares traded in the recent trading session. The company, currently valued at $1.68B, closed the recent trade at $8.03 per share which meant it gained $0.21 on the day or 2.75% during that session. The BCRX stock price is -18.31% off its 52-week high price of $9.50 and 49.81% above the 52-week low of $4.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.64 million shares traded. The 3-month trading volume is 3.44 million shares.
The consensus among analysts is that Biocryst Pharmaceuticals Inc (BCRX) is Buy stock at the moment, with a recommendation rating of 1.18. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 13 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.05.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) trade information
Sporting 2.75% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the BCRX stock price touched $8.03 or saw a rise of 1.71%. Year-to-date, Biocryst Pharmaceuticals Inc shares have moved 6.85%, while the 5-day performance has seen it change 8.58%. Over the past 30 days, the shares of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) have changed -0.19%. Short interest in the company has seen 20.73 million shares shorted with days to cover at 5.78.
Wall Street analysts have a consensus price target for the stock at $16, which means that the shares’ value could jump 49.81% from the levels at last check today.. The projected low price target is $7.0 while the price target rests at a high of $25.0. In that case, then, we find that the latest price level in today’s session is -211.33% off the targeted high while a plunge would see the stock lose 12.83% from the levels at last check today..
Biocryst Pharmaceuticals Inc (BCRX) estimates and forecasts
The company’s shares have gained 5.45% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 25.04%.
9 analysts offering their estimates for the company have set an average revenue estimate of 127.92M for the current quarter. 9 have an estimated revenue figure of 139.33M for the next ending quarter. Year-ago sales stood 92.76M and 109.33M respectively for this quarter and the next, and analysts expect sales will grow by 37.90% for the current quarter and 25.04% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 14.52% over the past 5 years.
BCRX Dividends
Biocryst Pharmaceuticals Inc is expected to release its next earnings report on 2025-Feb-23 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Major holders
Insiders own 1.41% of the company shares, while shares held by institutions stand at 81.21% with a share float percentage of 82.37%. Investors are also buoyed by the number of investors in a company, with Biocryst Pharmaceuticals Inc having a total of 346.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 19.96 million shares worth more than $123.33 million. As of 2024-06-30, BLACKROCK INC. held 9.6676% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 18.77 million shares as of 2024-06-30. The firm’s total holdings are worth over $116.0 million and represent 9.0926% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 3.11% shares in the company for having 6.5 shares of worth $52.26 million while later fund manager owns 5.43 shares of worth $43.65 million as of Mar 31, 2025 , which makes it owner of about 2.60% of company’s outstanding stock.
